Skip to main content

Table 1 Summary of patients being included. Previous treatment (1: yes; 0: no): OP surgery, RTx radiotherapy, AHT anti-hormonal therapy (including second line AHT with bicalutamide, enzalutamide, abiraterone acetate), CTx chemotherapy (docetaxel, cabazitaxel), Ra-223 radium-223 dichloride

From: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Patient

Age

Activity (GBq)

PSA (ng/ml) prior to therapy

Gleason score

Previous treatment

OP

RTx

AHT

CTx

Ra-223

1

61

7.44

25.9

9

0

1

1

1

0

2

75

7.46

38.4

9

1

0

1

1

0

3

75

7.44

1070

8

1

1

1

1

1

4

78

9.04

570

9

0

0

1

1

0

5

62

7.47

848

-

0

1

1

0

0

6

59

7.47

5.38

7b

0

1

1

1

0

7

74

9.19

1696

-

1

1

1

0

0

8

63

7.46

149

8

0

1

1

1

0

9

82

7.44

20.2

9

1

1

1

0

0

10

70

7.42

127

9

1

1

1

1

1

11

75

9.05

436

9

0

1

1

1

0

12

49

9.00

121

9

1

1

1

1

1

13

64

7.47

1268

8

0

1

1

1

0

14

79

7.46

72.7

7b

0

0

1

0

0

15

73

9.04

19.6

9

1

0

1

1

0